

Special Issue

Tumorigenesis Mechanism of Colorectal Cancer

Message from the Guest Editor

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second deadliest cancer worldwide. CRC accounts for approximately 10% of cancer-related deaths in men and women. Although screening techniques and treatment have progressed substantially in recent years, the prevalence of CRC is still on the rise. Therefore, further studies are necessary to determine the molecular mechanisms that underline CRC initiation and progression. In this Special Issue, we are pleased to invite authors to submit articles addressing recent advances regarding the mechanistic pathways involved in CRC tumorigenesis. This Special Issue was established to prompt researchers to perform studies on the following subjects in CRC:

- Mechanistic pathways involved in the evolution of primary, metastatic, and recurrent lesions;
- Metabolism dysregulation;
- The molecular mechanisms of resistance to anti-cancer agents;
- The role of extracellular vesicles in tumorigenesis.

Basic studies or translational studies are welcome. Reviews are also appreciated.

Guest Editor

Dr. Miran Rada

Department of Anatomy and Cell Biology, McGill University, Montreal, QC H3A 0G4, Canada

Deadline for manuscript submissions

closed (31 August 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/150972

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)